Clinical Trials
14 trialsNCT06915766 2026-05-08
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Cogent Biosciences, Inc.
Available
NCT05593185 2026-04-24
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
Sellas Life Sciences Group
Available
NCT07215832 2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT07346105 2026-01-16
Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies
Orca Biosystems, Inc.
Temporarily not available
NCT04360005 2025-12-05
Managed Access Programs for ABL001, Asciminib
Novartis
Available
NCT04745637 2025-11-18
Managed Access Programs for INC424, Ruxolitinib
Novartis
Available
NCT05269771 2025-11-05
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
Novartis
No longer available
NCT05219266 2024-06-28
Managed Access Programs for PKC412, Midostaurin
Novartis
No longer available
NCT03592576 2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available
NCT04518644 2023-04-28
Nilotinib, for Patients With CML-CP or CML-AP
Novartis
No longer available
NCT01592136 2018-02-06
Expanded Access Program of Ponatinib
Takeda
Approved for marketing
NCT00905593 2012-07-18
ENACT
Novartis
Approved for marketing
NCT00302016 2011-08-26
Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia
Novartis
No longer available
NCT00413270 2011-07-13
Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant
Novartis
No longer available